2,253 results on '"Marcel"'
Search Results
2. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
3. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract
4. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease
5. Impact of etoposide and ASCT on survival among patients aged
6. Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis
7. Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant
8. Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease
9. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
10. The protein landscape of chronic lymphocytic leukemia
11. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis
12. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study
13. Plasmodium falciparum sexual parasites develop in human erythroblasts and affect erythropoiesis
14. An intestinal organoid–based platform that recreates susceptibility to T-cell–mediated tissue injury
15. Endothelial protein C receptor supports hematopoietic stem cell engraftment and expansion in Mpl-deficient mice
16. Pediatric T-cell lymphoblastic lymphomas but not leukemias harbor TRB::NOTCH1fusions with unfavorable outcome
17. What’s brewing for MALT1 in lymphoma?
18. Pediatric T-cell lymphoblastic lymphomas but not leukemias harbor TRB::NOTCH1 fusions with unfavorable outcome
19. Nrf2 regulates CD4+ T cell–induced acute graft-versus-host disease in mice
20. Impact of gut colonization with butyrate-producing microbiota on respiratory viral infection following allo-HCT
21. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins
22. How I treat disseminated intravascular coagulation
23. Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease
24. Polyphosphate nanoparticles on the platelet surface trigger contact system activation
25. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease
26. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease
27. A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
28. A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
29. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
30. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use
31. Genomic Landscaping of Post-Transplant Lymphoproliferative Disorders Using Circulating Tumor DNA
32. Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma
33. Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
34. Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)
35. Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy
36. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
37. Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival
38. Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders
39. Microbial Bile Acid Metabolism Shapes Effector T Cell Responses during Inflammation in Mouse and Human
40. Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
41. Microbial Changes in Response to a Plant-Based Diet and/or Supplements in SMM Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via Healthtree: The Nutrition Prevention (NUTRIVENTION-2) Study
42. Outcome of Transformed Marginal Zone Lymphoma: A Population Based Study
43. Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen
44. Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease
45. The forkhead transcription factor FOXP1 represses human plasma cell differentiation
46. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality
47. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
48. A phase 2 study of Interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract
49. Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations
50. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.